RxDoctor Payments Data

Debasish Mridha, MD

Neurology · Saginaw, MINPI 1851327159

Payments from drug & device makers

$24,230in general payments, 2019–2025

Across 1,471 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • EMD Serono, Inc.$2K
  • Biogen$2K
  • UCB, Inc.$2K
  • Novartis$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$1411%
  • Food & beverage$23,77298%
  • Education$3171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)110$2,242
EMD Serono, Inc.183$2,151
Biogen116$1,829
UCB, Inc.102$1,667
Novartis97$1,562
Teva Pharmaceuticals USA, Inc.84$1,154
Eisai Inc.55$973
Harmony Biosciences LLC53$839
Amgen(2 entities)51$836
AstraZeneca(2 entities)50$825
Sanofi39$761
Lilly USA, LLC37$715
Neurocrine Biosciences, Inc.35$662
Pfizer41$613
Biohaven Pharmaceuticals, Inc.12$564
Sunovion Pharmaceuticals Inc.40$477
Bristol Myers Squibb29$429
Catalyst Pharmaceuticals, Inc.20$408
Jazz Pharmaceuticals Inc.21$402
Otsuka America Pharmaceutical, Inc.20$368
Amneal Pharmaceuticals LLC18$336
Supernus Pharmaceuticals, Inc.23$330
Lundbeck LLC15$320
Kyowa Kirin, Inc.21$316
Neurelis, Inc.17$302
Johnson & Johnson(2 entities)14$293
MDD US Operations, LLC25$283
Biohaven Pharmaceutical Holding Company Ltd.16$282
Vanda Pharmaceuticals Inc.16$228
Adamas Pharmaceuticals, Inc.11$200
Acorda Therapeutics, Inc8$163
Genentech USA, Inc.8$151
Avadel CNS Pharmaceuticals, LLC7$144
Tanabe Pharma America, Inc.6$136
Acadia Pharmaceuticals Inc8$128
Avanir Pharmaceuticals, Inc.6$107
Corium, LLC6$96
SK Life Science, Inc.5$89
Sumitomo Pharma America, Inc.4$77
Kowa Pharmaceuticals America, Inc.4$70
Argenx US, Inc.3$61
Medtronic2$56
CSL Behring2$52
Livanova USA, Inc.2$44
Mallinckrodt Enterprises LLC3$43
Arbor Pharmaceuticals, Inc.3$39
Alnylam Pharmaceuticals Inc.2$31
E.r. Squibb & Sons, L.L.C.2$30
TG Therapeutics, Inc.1$28
Assertio Therapeutics, Inc.2$26
Axsome Therapeutics, Inc.1$24
Springworks Therapeutics, Inc.1$24
Aucta Pharmaceuticals, Inc.1$23
Takeda Pharmaceuticals U.S.A., Inc.1$23
Hospira, Inc.1$22
Merz Pharmaceuticals, LLC1$20
ZOLL Respicardia, Inc.1$19
Octapharma USA, Inc.1$19
Almatica Pharma LLC1$19
Grifols USA, LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,230 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$202,682
Medicare patients
252
Services billed
3,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine30$270,607
AubagioTeriflunomide26$239,734
VumerityDiroximel Fumarate26$221,311
Kesimpta PenOfatumumab15$165,731
BetaseronInterferon Beta-1b15$147,035
ZeposiaOzanimod Hydrochloride13$111,915
WakixPitolisant Hcl14$91,475
AptiomEslicarbazepine Acetate38$72,869
Nurtec OdtRimegepant Sulfate31$61,159
FycompaPerampanel14$41,250
Emgality PenGalcanezumab-Gnlm22$30,928
Ajovy AutoinjectorFremanezumab-Vfrm22$28,639
BriviactBrivaracetam22$23,515
TopamaxTopiramate16$21,547
UbrelvyUbrogepant12$18,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,154$270,60730 claims
SanofiAubagio$761$239,73426 claims
BiogenVumerity$1,829$221,31126 claims
E.r. Squibb & Sons, L.L.C.Zeposia$30$111,91513 claims
Harmony Biosciences LLCWakix$839$91,47514 claims
Sunovion Pharmaceuticals Inc.Aptiom$477$72,86938 claims
PfizerNurtec Odt$613$61,15931 claims
UCB, Inc.Briviact, Nayzilam, Neupro$1,667$50,82345 claims
Eisai Inc.Fycompa$973$41,25014 claims
AbbVieUbrelvy$2,242$18,40112 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$336$1,88925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →